Forte Biosciences (FBRX) Other Non-Current Assets (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Other Non-Current Assets of $2.0 million for Q1 2026, up 7912.0% year-over-year from $25000.0 in Q1 2025, and down 2.81% quarter-over-quarter from $2.1 million in Q4 2025.
Powered by 
Analysis
Forte Biosciences (FBRX) Other Non-Current Assets (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Other Non-Current Assets for 11 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 7912.0% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $2.0 million (up 7912.0% YoY), while the FY2025 annual figure was $2.1 million, up 1393.48% from the prior year.
- Other Non-Current Assets retreated to $2.0 million in Q1 2026 per FBRX's latest filing, from $2.1 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $2.1 million in Q4 2025 and bottomed at $12000.0 in Q1 2023.
- Historically, Other Non-Current Assets has averaged $529058.8 across 5 years, with a median of $192000.0 in 2024.
- Annual changes were most pronounced in 2025 — Other Non-Current Assets tumbled 93.89% — and 2026, when it soared 7912.0%.
- Forte Biosciences' Other Non-Current Assets stood at $13000.0 in 2022, then surged by 4084.62% to $544000.0 in 2023, then sank by 74.63% to $138000.0 in 2024, then soared by 1393.48% to $2.1 million in 2025, then declined by 2.81% to $2.0 million in 2026.
- Business Quant data shows FBRX's Other Non-Current Assets at $2.0 million in Q1 2026, $2.1 million in Q4 2025, and $1.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | 2.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.55 Mn |
| Mar 31, 2026 | 2.00 Mn |
| Dec 31, 2025 | 2.06 Mn |
| Sep 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 57,000.00 |
| Mar 31, 2025 | 176,000.00 |
| Dec 31, 2024 | 138,000.00 |
| Sep 30, 2024 | 192,000.00 |
| Jun 30, 2024 | 271,000.00 |
| Mar 31, 2024 | 409,000.00 |
| Dec 31, 2023 | 544,000.00 |
| Sep 30, 2023 | 679,000.00 |
| Jun 30, 2023 | 407,000.00 |
| Mar 31, 2023 | 437,000.00 |
| Dec 31, 2022 | 486,000.00 |
| Sep 30, 2022 | 534,000.00 |
| Jun 30, 2022 | 874,000.00 |
| Mar 31, 2022 | 893,000.00 |
| Dec 31, 2021 | 786,000.00 |
| Sep 30, 2021 | 834,000.00 |